603367.SH
辰欣药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 13.61
−3.48%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.4B | 3.4B | 4.0B | 4.5B | 4.1B |
| Cost of Revenue | 1.6B | 1.7B | 1.7B | 1.8B | 1.8B |
| Gross Profit | 1.7B | 1.8B | 2.3B | 2.6B | 2.3B |
| Operating Expenses | |||||
| R&D Expense | 273.6M | 285.8M | 342.6M | 374.9M | 335.2M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 247.3M | 242.6M | 301.4M | 292.4M | 259.7M |
| Selling & Marketing Expense | 856.6M | 888.2M | 1.1B | 1.3B | 1.3B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.4B | 1.4B | 1.8B | 2.0B | 1.9B |
| Cost and Expenses | 3.0B | 3.1B | 3.5B | 3.9B | 3.7B |
| Operating Income (EBIT) | 483.8M | 499.9M | 572.0M | 592.6M | 364.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 480.0M | 496.2M | 575.8M | 595.9M | 366.2M |
| Income Tax Expense | 66.9M | 70.6M | 60.8M | 70.4M | 13.9M |
| Bottom Line | |||||
| Net Income | 408.5M | 421.2M | 508.9M | 521.3M | 350.0M |
| Earnings from Cont. Ops | 413.1M | 425.6M | 514.9M | 525.4M | 352.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 408.5M | 421.2M | 508.9M | 521.3M | 350.0M |
| Per Share | |||||
| Basic EPS | CN¥0.90 | CN¥0.93 | CN¥1.12 | CN¥1.15 | CN¥0.77 |
| Diluted EPS | CN¥0.90 | CN¥0.93 | CN¥1.12 | CN¥1.15 | CN¥0.77 |
| Revenue Per Share | CN¥7.49 | CN¥7.60 | CN¥8.76 | CN¥9.84 | CN¥8.95 |
| Shares | |||||
| Basic Shares Outstanding | 450.8M | 453.0M | 454.4M | 453.3M | 454.5M |
| Diluted Shares Outstanding | 450.8M | 453.0M | 454.4M | 453.3M | 454.5M |
| Profitability Metrics | |||||
| EBITDA | — | 699.4M | 794.9M | 825.3M | 594.1M |
| D&A | — | 199.6M | 222.8M | 232.7M | 229.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026